Share on LinkedInShare on LinkedIn

ARTICLE · 27 DECEMBER 2024

Market Intelligence Thought Leadership Award Winner

An Early Christmas Present For Combination Products

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

As always, the CJEU continue to refine the rules regarding obtaining SPCs in Europe. The latest judgment on combination products leaves both gifts and a lump of coal in the stocking of patent holders...

United KingdomIntellectual Property

As always, the CJEU continue to refine the rules regarding obtaining SPCs in Europe. The latest judgment on combination products leaves both gifts and a lump of coal in the stocking of patent holders (forgive me if the Christmas metaphor is becoming strained!)

In combined cases C-119/22 and C-149/22, the Court was asked to rule on whether it is possible to obtain an SPC on a combination product (here, metformin and sitagliptin; and ezetimibe and simvastatin) when an SPC had already been granted on a product containing the first of those actives alone. Further, if the "inventive advance" of the basic patent is only in connection with one of the actives (and the second was already known at the relevant priority date), does this make a difference?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from